Esperion Therapeutics, Inc. operates as a pharmaceutical company primarily focused on developing and commercializing medications designed to manage elevated low-density lipoprotein (LDL) cholesterol levels in patients. Its flagship pharmaceutical products include NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) in tablet form. These treatments are prescribed for individuals suffering from atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH).